title: NK-3 receptor antagonism prevents behavioral sensitization to cocaine: a role of glycogen synthase kinase-3 in the nucleus accumbens.
abstract: Repeated administration of cocaine induces heightened behavioral hyperactivity termed sensitization. Although NK-3 receptors have been shown to modulate acute cocaine-induced behaviors, their role in behavioral sensitization is unknown. The present study investigated whether NK-3 receptor blockade altered behavioral sensitization to cocaine. Additionally, glycogen synthase kinase-3 (GSK3) has been shown to be involved in dopamine receptor signaling and in development of sensitization; therefore regulation of GSK3 activity in the nucleus accumbens was also investigated. Administration of the NK-3 receptor antagonist SB 222200 (5 mg/kg, s.c.) prior to repeated cocaine (20 mg/kg, i.p.) prevented the development of sensitized responses after a cocaine challenge. Pre-treatment with SB 222200 before a cocaine challenge also blocked expression of sensitization. Decrease in GSK3 activity demonstrated by increased phosphorylation of GSK3α and GSK3β was detected 20 mins after an acute cocaine injection. In contrast, a cocaine challenge failed to alter phosphorylation of GSK3α and GSK3β in sensitized mice. SB 222200 prior to repeated cocaine resulted in increased phosphorylation of GSK3α and GSK3β akin to changes following acute cocaine. Collectively, these findings demonstrate the involvement of NK-3 receptors in development and expression of behavioral sensitization and in regulation of GSK3 activity in the nucleus accumbens after repeated cocaine.
authors.affiliation: Department of Pharmacology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA. cnwanesh@temple.edu
authors.forename: Chinwe A
authors.initials: CA
authors.lastname: Nwaneshiudu
authors.forename: Ellen M
authors.initials: EM
authors.lastname: Unterwald
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D003042:Cocaine / Q000494:pharmacology*; D004298:Dopamine / Q000502:physiology; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology*; D038362:Glycogen Synthase Kinase 3 / Q000502:physiology*; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009714:Nucleus Accumbens / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D010766:Phosphorylation; D011804:Quinolines / Q000494:pharmacology; D011954:Receptors, Dopamine / Q000502:physiology; D018042:Receptors, Neurokinin-3 / Q000037:antagonists & inhibitors*; D015398:Signal Transduction / Q000502:physiology
chemical_list: D018765:Dopamine Uptake Inhibitors; D011804:Quinolines; D011954:Receptors, Dopamine; D018042:Receptors, Neurokinin-3; C109112:SB 222200; D038362:Glycogen Synthase Kinase 3; D003042:Cocaine; D004298:Dopamine
references.citation: FEBS Lett. 1996 Dec 16;399(3):333-8
references.pmid: 8985174
references.citation: Neuropharmacology. 2009 Jun;56(8):1116-23
references.pmid: 19328817
references.citation: Brain Res. 1995 Oct 9;695(1):19-24
references.pmid: 8574643
references.citation: Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274-8
references.pmid: 2899326
references.citation: Brain Res Brain Res Rev. 1991 Sep-Dec;16(3):223-44
references.pmid: 1665095
references.citation: Synapse. 1993 Aug;14(4):314-23
references.pmid: 8161369
references.citation: Neuropharmacology. 2009 Sep;57(3):295-301
references.pmid: 19500601
references.citation: Neuroscience. 1989;32(2):323-35
references.pmid: 2479882
references.citation: Prog Neurobiol. 2001 Nov;65(4):391-426
references.pmid: 11527574
references.citation: J Pharmacol Exp Ther. 2000 Oct;295(1):373-81
references.pmid: 10992004
references.citation: Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):5099-104
references.pmid: 15044694
references.citation: Eur J Pharmacol. 1996 Dec 27;318(1):31-5
references.pmid: 9007509
references.citation: J Pharmacol Exp Ther. 1996 Aug;278(2):490-502
references.pmid: 8768696
references.citation: Neuron. 2000 Mar;25(3):515-32
references.pmid: 10774721
references.citation: Eur J Neurosci. 2007 Apr;25(8):2457-72
references.pmid: 17445241
references.citation: Pharmacol Biochem Behav. 1981 Oct;15(4):559-62
references.pmid: 7197373
references.citation: Neuropeptides. 1998 Oct;32(5):481-8
references.pmid: 9845011
references.citation: Mol Cell Biol. 2000 Dec;20(24):9356-63
references.pmid: 11094086
references.citation: J Comp Neurol. 1988 Jun 1;272(1):90-113
references.pmid: 2454979
references.citation: Science. 2003 Nov 21;302(5649):1412-5
references.pmid: 14631045
references.citation: Eur J Neurosci. 1999 May;11(5):1598-604
references.pmid: 10215912
references.citation: Neuropharmacology. 1993 Apr;32(4):387-91
references.pmid: 8497339
references.citation: Brain Res Brain Res Rev. 1997 Oct;25(2):192-216
references.pmid: 9403138
references.citation: J Neurochem. 2009 Dec;111(6):1357-68
references.pmid: 19799712
references.citation: Neuropsychopharmacology. 2005 Aug;30(8):1443-54
references.pmid: 15770241
references.citation: J Comp Neurol. 1992 Mar 22;317(4):341-56
references.pmid: 1374442
references.citation: Br J Pharmacol. 1992 Jan;105(1):3-5
references.pmid: 1375857
references.citation: Eur J Pharmacol. 1991 Mar 19;195(1):107-14
references.pmid: 1712305
references.citation: J Neurochem. 2008 Mar;104(6):1440-9
references.pmid: 18221378
references.citation: J Neurochem. 2007 Oct;103(2):706-13
references.pmid: 17635666
references.citation: Commun Psychopharmacol. 1979;3(5):285-90
references.pmid: 575770
references.citation: J Pharmacol Exp Ther. 1998 Sep;286(3):1171-6
references.pmid: 9732375
references.citation: Neuropharmacology. 2009;56 Suppl 1:160-8
references.pmid: 18657553
references.citation: J Neurosci. 2006 Aug 30;26(35):9022-9
references.pmid: 16943560
references.citation: Am J Addict. 2001 Summer;10(3):201-17
references.pmid: 11579619
references.citation: J Pharmacol Exp Ther. 1994 Sep;270(3):1387-96
references.pmid: 7932193
references.citation: Eur J Pharmacol. 1992 Mar 17;213(1):165-6
references.pmid: 1379929
references.citation: Science. 1987 Sep 4;237(4819):1219-23
references.pmid: 2820058
references.citation: Brain Res. 2004 Oct 8;1023(1):126-33
references.pmid: 15364027
references.citation: Addiction. 2001 Jan;96(1):103-14
references.pmid: 11177523
references.citation: J Neurosci. 2002 Oct 15;22(20):8911-21
references.pmid: 12388598
references.citation: Nature. 1976 Apr 22;260(5553):731-2
references.pmid: 944382
references.citation: Psychopharmacology (Berl). 2000 Aug;151(2-3):99-120
references.pmid: 10972458
references.citation: J Neurosci. 2002 Jul 15;22(14):5817-22
references.pmid: 12122043
references.citation: Pharmacol Ther. 2005 Jun;106(3):389-403
references.pmid: 15922019
references.citation: Ann N Y Acad Sci. 1990;579:254-72
references.pmid: 2159744
references.citation: Neuroscience. 2001;102(4):843-51
references.pmid: 11182247
references.citation: J Pharmacol Exp Ther. 1997 May;281(2):699-706
references.pmid: 9152375
references.citation: Eur J Pharmacol. 2006 May 1;536(3):269-78
references.pmid: 16603151
references.citation: J Psychopharmacol. 1998;12(1):49-53
references.pmid: 9584968
references.citation: Eur J Neurosci. 2006 Sep;24(6):1721-32
references.pmid: 17004936
references.citation: Brain Res Bull. 2010 May 31;82(3-4):184-7
references.pmid: 20347018
references.citation: Brain Res Mol Brain Res. 1998 Feb;54(1):141-51
references.pmid: 9526067
references.citation: Peptides. 2006 Sep;27(9):2214-23
references.pmid: 16621146
references.citation: J Pharmacol Exp Ther. 1991 Sep;258(3):882-90
references.pmid: 1890623
references.citation: J Biol Chem. 1951 Nov;193(1):265-75
references.pmid: 14907713